Tissue Bank
Latest round
- Series D
Last raised
- Nov 2018
Total raised
- Undisclosed
Investors
- 5
About Tissue Bank
Established in 2011 and based in Shanghai, China, Tissue Bank is a biotechnology company mainly engaged in the development of transplantation immunotherapy technology. The branches have been set up in Shenzhen and Xi'an. In 2023, the reproductive immunity and general examination business was started. The Chairman of the board and Founder, Zhongzheng Zheng, graduated from Xiamen University, and he is a member of Civil Construction. The company is committed to the fields of immunology, including scientific research, tissue storage, immunotherapy evaluation, and diagnostic reagents. It provides testing services for various types of diseases mediated by immunity such as clinical blood and body fluid testing, clinical cell molecular genetics testing, etc. It has built a series of high-throughput sequencing platforms including HiSeq X Ten, NextSeq 500, MiSeq, and so on.
Who invested in Tissue Bank
5 investors across 4 rounds
See all investors in Tissue Bank
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Tissue Bank
Who invested in Tissue Bank?
Tissue Bank has 5 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tissue Bank raised?
Tissue Bank has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Tissue Bank last raise money?
Tissue Bank's most recent round on record is a Series D, in Nov 2018.
What does Tissue Bank do?
Established in 2011 and based in Shanghai, China, Tissue Bank is a biotechnology company mainly engaged in the development of transplantation immunotherapy technology.
Where is Tissue Bank headquartered?
Tissue Bank is headquartered in Shanghai, China.
Which VCs invest in companies like Tissue Bank?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Tissue Bank's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Tissue Bank? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.